|Bid||1.9700 x 42300|
|Ask||1.9800 x 42300|
|Day's Range||1.9700 - 2.1100|
|52 Week Range||1.5000 - 10.3200|
|Beta (5Y Monthly)||1.59|
|PE Ratio (TTM)||9.21|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Aurora Cannabis (NYSE:ACB) has pulled a nice rally during the past couple weeks. Over this time, ACB stock has gained about 24% to hit $2.04.Source: Shutterstock Of course, this is little consolation for long-term holders. A year ago ACB was fetching a much more robust price of $10.No doubt, the rest of industry has seen steep declines as well. Just look at the charts for companies like Tilray (NASDAQ:TLRY), Canopy Growth (NYSE:CGC) and Cronos Group (NASDAQ:CRON).InvestorPlace - Stock Market News, Stock Advice & Trading TipsAs for Aurora, there are certainly some bigtime challenges for the company. First of all, Aurora pulled off a string of acquisitions, which ballooned the company's debt and added lots of complexity to the organization. It also did not help that several Wall Street analysts put out awful reports, such as Piper Sandler's Michael Lavery, who slapped a $1 price target on ACB stock. But the worst of all came from GLJ Research analyst Gordon Johnson, who says Aurora stock will hit $0 within the next two years! * Invest in America's Most Trusted Brands With These 7 Stocks to Buy But hey, analysts are far from perfect. The fact is that Wall Street can get overly gloomy, especially when a sector goes out of favor.However, this can present opportunities. With sentiment so bad right now, it won't take much good news to perk up the stock price.So what is the bull case for ACB stock and what are the drivers? Canadian Market and ACB StockThe problems with the Canadian market aren't really about demand. Rather, they're about distribution and enforcement. An onerous government process has made it extremely difficult go launch new retail locations. In the meantime, there has emerged more black market activities that have generally not been checked by the authorities.Consider this: there are a mere 363 cannabis stores across Canada. That's just one location for every 14,3188 cannabis users. Given this, it should be no surprise that companies like ACB have struggled.Yet this will not be permanent. There are signs that Canadian authorities are being more proactive -- and this should go a long way to help improve Aurora's fortunes.But there should be another catalyst -- "Cannabis 2.0." This refers to the legalization of cannabis edibles and beverages in Canada, which could be a multi-billion dollar opportunity for the sector.Here's what Aurora CEO Cam Battley said about this during the latest earnings call: "The initial suite of new products that we will launch include vapes, concentrates, gummies, chocolates, mints and cookies. We've selectively partnered with a variety of organizations, prioritized our resources and built the inventory to help ensure consumers across Canada will have access to our high-quality derivative products." Fiscal RestraintAurora is already taking actions to cut back on expenses. The company has initiated construction deferrals and slowed commissioning of projects, which is expected to save $200 million "in the near term." The company also retired $227 million of a 5% unsecured convertible debenture that had a due date of March 2020. What's more, if revenues continue to increase as the situation in Canada improves, this will definitely alleviate the pressures.It's also important to keep in mind that Aurora has Nelson Peltz as a strategic advisor. He is one of the world's top investors for consumer stocks, with positions in companies like Procter & Gamble (NYSE:PG), Mondelez (NASDAQ:MDLZ) and Wendy's (NASDAQ:WEN). In other words, he should be a great source of strategic advice, but should also provide key introductions to other investors and corporate partners.Tom Taulli is the author of the book, Artificial Intelligence Basics: A Non-Technical Introduction. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks on the Move Thanks to the Davos World Economic Forum * Invest in America's Most Trusted Brands With These 7 Stocks to Buy * 7 Earnings Reports to Watch Next Week The post Key Catalysts Will Get Risky Aurora Stock Back On Track appeared first on InvestorPlace.
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $2.07, marking a +1.47% move from the previous day.
2019 was a year cannabis investors would like to forget, including Aurora Cannabis (NYSE:ACB) shareholders. But it still might be optimistic to assume cannabis stocks have bottomed out. The same holds true for ACB stock, and I maintain a bearish view for 2020. I believe that balance sheet concerns coupled with industry headwinds will ensure bearish sentiments sustain due to key challenges coming up in the near to medium term.Source: Shutterstock Unfortunately for ACB stock, there is no dearth of reasons to be bearish.Piper Sandler analyst Michael Lavery opined that the stock is headed for a target of $1. Christopher Carey, analyst at Bank of America Merrill Lynch, assigned a "sell" rating to ACB stock. Both analysts cited balance sheet problems as one of the company's key challenges. Additionally, in December 2019 Owen Bennett, analyst at Jefferies, downgraded Aurora Cannabis from "buy" to "hold." The point I'm making is that the markets have a very bearish view of the stock, and there are strong reasons to remain pessimistic.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Balance Sheet Stress and Dilution RiskOne of the primary reasons for downgrading ACB stock has been the pressure on the balance sheet. For the first quarter of fiscal year 2020, Aurora Cannabis reported cash and equivalents of 153 million CAD. For the same quarter, the cash used in operations was 95 million CAD. * The 7 Stocks That Cautious Investors Should Sell Now If cash burn sustains at the same rate, Aurora Cannabis will need additional equity or debt funding in the second half of 2020. That seems very likely and the stock is discounting dilution or leveraging concerns, among others. There are two major potential negative triggers.First, the year 2020 is likely to see high marketing and selling expenses. The company is rolling out "cannabis 2.0" products including gummies, chocolates, baked goods and mints. With higher marketing expenses, ACB will burn cash faster and dilution is likely sooner.Second, if these "cannabis 2.0" products fail to gain traction, ACB stock will trend lower. The company is relying on recreational cannabis to trigger growth in the medium-term. Medicinal cannabis is unlikely to be a growth trigger since clinical research and regulatory approval will take time. The Long Path to Medicinal Cannabis GrowthAurora Cannabis is looking at medicinal cannabis as one of its major growth triggers. However it seems overly optimistic to expect growth from this segment in the next 12 to 24 months.According to the U.S. Food & Drug Administration, the only approved CBD drug is Epidiolex. The FDA has specifically warned that "selling unapproved products with unsubstantiated therapeutic claims is not only a violation of the law, but also can put patients at risk."There is no shortcut to inroads for the medicinal cannabis segment. Progress will be slow and the markets have been discounting this factor. Aurora Cannabis is working on clinical research related to pain, epilepsy, PTSD, anxiety, opioid sparing, cancer and neurodegeneration. If results are positive in the coming years, medicinal cannabis will gain traction. But investment in clinical trials and research and development will involve sustained cash burn. Setback in EuropeBesides growth in Canada, Aurora Cannabis is focused on Europe for growth. However, the company had few setbacks in the recent past and that adds to the negative triggers.In November 2019, Aurora Cannabis products were suspended from Germany until further notice. The German authorities are investigating the methods used by Aurora Cannabis to increase the shelf life of cannabis. The important point to note is that German cannabis market is expected to be worth $9.4 billion by 2028. Therefore, this is a big setback in a high potential market.Further, in November 2019, Italy cancelled one of the three lots of cannabis supplied by Aurora. The given reason was noncompliance with European Union Good Manufacturing Practice standards.These incidents could impact growth and regulatory hurdles are a major headwind. The Bottom Line On ACB StockACB stock has been battered in 2019 and I don't see any respite in 2020. Cash burn remains a big challenge, and additionally, I believe that slow growth in medicinal cannabis segment will affect stock sentiment.The industry is still at a stage where R&D and marketing expenses are set to remain high in coming years. Therefore, equity dilution or leveraging is likely in 2020 and can further depress ACB stock.Overall, it makes sense to stay away from Aurora Cannabis even after the big decline of 2019.As of this writing, Faisal Humayun did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Stocks That Cautious Investors Should Sell Now * 7 Healthcare Stocks With 100% Street Support * 3 Chinese Stocks to Buy, Sell, or Play from Either Side The post ACB Stock Bearish Due to High Balance Sheet Stress appeared first on InvestorPlace.
The Canadian cannabis sector has never marketed itself as a stable, worry-free opportunity. However, some names are worse than others -- as is the case with Aurora Cannabis (NYSE:ACB). Once a bright spot in legal marijuana due to its massive international footprint, ACB stock plummeted in 2019 as fiscal concerns weighed more heavily than the company's potential opportunities. With shares off to a rocky start to 2020, is there any hope here?Source: Shutterstock Investors have every right to be concerned. Since the last session of 2019, ACB stock appeared determined to kill every holding hands' patience. At one point, the markets feared that shares could fall below $1. However, some positive notes -- or at least, non-overtly negative notes -- brought some life back into the embattled shares.In a note to clients, Cowen analyst Vivien Azer described attending an investors conference, where Aurora Cannabis' management team disclosed that it was working with creditors to restructure its debt. Also, Cantor Fitzgerald analyst Pablo Zuanic called for the company to find a better CEO.InvestorPlace - Stock Market News, Stock Advice & Trading TipsClearly, ACB stock can use any help that it can get, and these suggestions are steps in the right direction. But, will it be enough to convince observers to speculate on the company? * The Top 5 Dow Jones Stocks to Buy for 2020 If you're even mildly risk averse, ACB stock is not for you. Although I see optimistic catalysts for the organization and the industry, time is the biggest enemy; And don't mistake the present situation: although management is trying to restructure its debt, what they're really asking for is more digits on the clock.If they get it, ACB stock could fly higher in 2020. However, as with anything cannabis related, that's a big "if." The Possible Case for a Recovery in ACB StockBefore we get into it, let's reiterate once again: Aurora Cannabis is only for speculators at this point. While it has a chance for recovery, many things have to go right -- and in time.With that out of the way, the catalyst for ACB stock is the possible improvement of the Canadian cannabis market's supply-chain issues and licensing backlogs. Specifically, Canada needs to approve more cannabis retail outlets and dispensaries to effectively feed demand. Failing that, it needs to feed demand based on efficiency metrics.Interestingly, Azer pointed out that Aurora's disappointing fiscal first-quarter revenue was at least partially attributable to "congested channel inventory…from initial inventory loading in anticipation of Ontario opening additional locations that has yet to occur."Importantly, this channel-inventory congestion isn't a lame excuse. In the third calendar quarter of 2019, Ontario had over two million adult cannabis users. However, it only had 75 stores open to serve this demand. Put differently, there are nearly 27,000 users per each store. Click to Enlarge Source: Chart by Josh Enomoto Unfortunately, this metric just won't do. Currently, Canada has nearly 5.2 million cannabis users total and only 363 stores nationwide. Doing the simple math, this breaks down to 14,318 stores per one cannabis user.Now, this last figure pales in comparison to the state of Colorado: it has approximately one store per every 10,000 residents! Be that as it may, the issue with the Canadian province of Ontario is that compared to other provinces, it's incredibly inefficient. Of course, what's really glaring is that Ontario is home to Canada's largest population of cannabis users.However, it's not just Ontario. Provinces like Quebec, Nova Scotia and Manitoba have relatively sizable cannabis user communities -- yet these markets too are grossly inefficient.Nonetheless, any improvement here could do wonders for ACB stock. Can the U.S. Improve Aurora's Chances?Another factor that could play a vital role for Aurora Cannabis is the legalization momentum in the U.S. Although marijuana remains a Schedule I drug, the federal government legalized hemp and hemp derivatives like cannabidiol, or CBD. This suggests that full legalization is becoming more of a reality than a pipe dream.Furthermore, the upcoming 2020 presidential election presents an interesting wrinkle for ACB stock. Primarily, the Democratic party has generally moved toward supporting both marijuana legalization and decriminalization initiatives. Senator Bernie Sanders has gone a step further, indicating that he'll legalize marijuana via executive action if necessary -- and at 4:20pm ET, no less.However, not everyone is quite onboard with such a proposal. For instance, former Vice President Joe Biden has flip-flopped on the legalization question. And if he wins the election, he probably wouldn't be the most supportive of that idea. Plus, President Donald Trump could win another term -- and as such, full legalization would clash with his law-and-order image.Still, a few powerful catalysts are poised to launch ACB stock, that much is for sure. The question is whether they can actually do so, and in quick enough time.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy as the 2020 Presidential Election Approaches * 5 Dividend Stocks With Low Payout Ratios and High Yields * 4 Post-Holiday Retail Stocks Still Worth a Look The post Aurora Cannabis Could Recover in 2020 if the Stars Align appeared first on InvestorPlace.
The cannabis sector has seen a huge rally over the last week and Aurora Cannabis (ACB) is no exception. Some general excitement over a competitor’s quarterly earnings report and some positive regulatory headlines from the U.S. have investors throwing caution to the wind again. The company still has too many unresolved risks to rush into the stock here just because a competitor beat quarterly estimates due to a large bulk wholesale deal.Money Losing OperationsThe firing of CCO Cam Battley and the placing of a facility on the market for sale at a price of C$17 million doesn’t alter the bleak financial prospects of Aurora Cannabis. In the last quarter alone, the Canadian cannabis company reported an EBITDA loss of C$39.7 million.A capex cut might help stem the cash flow burn, but Aurora Cannabis has made limited steps announced to the public on the operational side. The company needs higher revenues and reduced costs in order to reach EBITDA profitable, a measure that doesn’t even factor in potentially mounting interest expenses into the cash burn equation.The big story coming up with the FQ2 results in mid-February is whether the company restructures operations to reduce the operating expense base of C$81.1 million. Aurora Cannabis already has solid gross margins near 60% so the key to success is matching the expense side of the equation with gross profits reduced by disappointing sales.Wholesale Sales The Organigram (OGI) earnings beat has the whole market up, but the company beat sales estimates based on a surprise bulk wholesale sale of C$9.2 million. Aurora Cannabis had a similar quarterly boost back in the June quarter where an additional C$18.0 million in bulk wholesale sales boosted those numbers sending the stock up to $6.50 back in September. The stock didn’t hold up at the end of 2019, partly because the September quarter sales saw wholesale revenues decline 50% to only C$10.3 million.The addition of competition in the wholesale space should hurt the ability of the company to repeat the revenue boost from bulk sales at 60% gross margins. Without the bulk sales, OrganiGram didn’t see any jump in revenues sequentially for the last quarter following the weak August quarter hit by lack of provinces ordering and product returns.Aurora Cannabis avoided the product returns hit, but the company saw sales dip last quarter. Investors shouldn’t expect any revenue boost this quarter outside of the wholesale sales. Analysts forecast December quarterly revenues of C$80 million which won’t inspire the market to chase this rally back above $2.With at least 1.2 billion shares outstanding, the stock has a market value of ~$2.5 billion and quarterly revenues of $60 million aren’t going to inspire investors to hold the sock assuming the adjusted EBITDA levels don’t show any major improvement.Consensus VerdictAll in all, the Street's current view on Aurora Cannabis is a mixed bag, indicating uncertainty as to its prospects. The stock has a Hold analyst consensus rating with only 3 recent "buy" ratings. This is versus 2 "hold" and 5 "sell" ratings. However, the $2.83 price target suggests an upside potential of nearly 40% from the current share price. (See Aurora Cannabis stock analysis on TipRanks)TakeawayThe key investor takeaway is that Aurora Cannabis has a lot of positive catalysts to play out in 2020, but the company needs to reorganize the firm to reduce operating expenses following delayed catalysts in 2020. The stock has seen a recent boost due to some over excitement about the rebound in sales at Organigram, but investors should be cautioned that the revenue beat was due to low quality sales.To find good ideas for cannabis stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
NEW YORK, NY / ACCESSWIRE / January 21, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis Inc. (“Aurora” or the “Company”) (ACB) and certain of its officers, on behalf of shareholders who purchased Aurora securities between October 23, 2018 through January 6, 2020, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between October 23, 2018 and January 6, 2020, inclusive (the "Class Period") of the important January 21, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.
Hagens Berman has filed a class action Complaint on behalf of investors in Aurora Cannabis Inc. (ACB). The firm alerts ACB investors of today’s deadline to move for lead plaintiff in a securities fraud class action pending against the Company and urges ACB investors who have suffered losses to contact the firm immediately.
NEW YORK, NY / ACCESSWIRE / January 20, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you ...
SAN FRANCISCO, CA / ACCESSWIRE / January 20, 2020 / Hagens Berman has filed a class action Complaint on behalf of investors in Aurora Cannabis Inc. (NYSE:ACB) . The firm urges ACB investors who have suffered ...
NEW YORK, NY / ACCESSWIRE / January 20, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
TUESDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aurora Cannabis Inc.
NEW YORK, Jan. 20, 2020 -- Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of GRUB, ACB, and MMSI. If you wish to serve.
I recently wrote that Aurora Cannabis (NYSE:ACB) stock isn't headed for $0, but it's still too early to buy. However, in the past couple of weeks, multiple Wall Street analysts have updated their outlook for Aurora. Some analysts are getting more pessimistic on the fundamental outlook for Aurora in the first half of 2020. Others are getting more bullish on the potential long-term value opportunity in Aurora stock.Source: Jarretera / Shutterstock.com Aurora's next earnings report is less than a month away. I think it's still too early to be buying the dip. Besides, there is at least one better option out there for speculative cannabis investors. Management Is ConfidentOne of the biggest Aurora bulls on Wall Street is Cantor Fitzgerald analyst Pablo Zuanic. Zuanic recently met with Aurora management. This week, he said he came away from the meeting even more convinced that Aurora's massive selloff is a buying opportunity.InvestorPlace - Stock Market News, Stock Advice & Trading TipsZuanic says there are three primary drivers of Aurora's underperformance in the past month, none of which are real reasons to sell the stock. First, CCO Cam Battley was let go. Zuanic says the market seems to think Battley resigned, but that's not the case. In fact, he says some more fresh blood would be good news for Aurora."We think ACB would benefit from some pruning and from bringing in an outside CEO renown in the investment community for both sound growth strategy and financial discipline (cost/cash flow)," Zuanic says. * 7 Earnings Reports to Watch Next Week Second, traders have been speculating that Aurora may significantly write-down the value of certain assets after a recent property listing price came in below expectations. Zuanic says Aurora's move to sell non-core assets is part of its cost management plans and should be considered good news for the balance sheet.Finally, Aurora's credit facility requires it to have a total funded debt-to-adjusted shareholders equity ratio at or below 0.25:1 by Sept. 30, 2020. Zuanic says all Aurora needs to get its ducks in order prior to this deadline is to generate around $21 million in earnings before interest, taxes depreciation and amortization (EBITDA) per quarter by the September quarter.Company management and Zuanic himself are confident that goal is still within reach."We would make use of the recent pullback," Zuanic said in conclusion. Cantor has an "overweight" rating and $3.85 price target for Aurora stock. Balance Sheet ConcernsThe same week Zuanic came out with his bullish commentary on Aurora, Bank of America analyst Christopher Carey downgraded the stock to "underperform." Carey also cut his price target to just $1.15.Like many Aurora bears, Carey's primary concern is the company's balance sheet."With [balance sheet] risks to remain a core investment thesis in 2020 in our view, and lingering uncertainty especially on financial covenants, we struggle to envision a scenario where shares have sustainable support," Carey wrote in the downgrade note.Carey credits Aurora with taking several steps to improve its balance sheet, including spending cuts, deferred capex and asset sales. However, he says Aurora is still not in position to meet the terms of its credit facility.Bank of America expects weakness in the Canadian cannabis market to continue throughout the first half of 2020. Without impressive growth numbers to support the bull thesis for cannabis stocks in the near-term, Carey says investors will remain focused on balance sheets. "Unfortunately, ACB has the weakest in our group, while valuation is still near group high," he said.In other words, Aurora has a lot of good things going for it. But at this point of uncertainty and at the current valuation, he simply can't recommend the stock. A Better Option Than Aurora StockLong-time readers know I've been like a broken record when it comes to cannabis stocks. There will likely ultimately be some huge winners in the space in the long term. But there is simply too much risk and uncertainty at this point to be picking one winner. * The 10 Best Value Stocks to Own in 2020 If you insist on picking one stock, I believe Canopy Growth Corp (NYSE:CGC) is the best pick in the space today. It certainly has a lot less risk than Aurora. Canopy has a strong balance sheet and a major financial backer in Constellation Brands (NYSE:STZ). In addition, I think there's a good chance Constellation may step in and buy out Canopy as soon as the financial outlook for cannabis stocks clears up.In the meantime, rather than buying a single stock, cannabis investors should consider owning a basket of at least four or five cannabis stocks to diversify their portfolio. Analysts expect the difficult cannabis market to persist in the first half of 2020. It would be wise for cannabis investors to consider clash flow, debt levels and valuation. In addition to Canopy, investors should consider other top-tier stocks such as Tilray (NASDAQ: TLRY) and Cronos Group (NASDAQ:CRON).As of this writing, Wayne Duggan did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The Top 5 Dow Jones Stocks to Buy for 2020 * 7 Fintech ETFs to Buy Now for Fabulous Financial Exposure * 3 Tech Stocks to Play Ahead of Earnings The post Is It Finally Time to Buy Aurora Cannabis Stock? appeared first on InvestorPlace.
(Bloomberg) -- Move over materials, there’s a new kid on the block. The C$300 billion ($230 billion) industrials group has ousted miners and forestry stocks to become the third-most valuable collection of companies on Canada’s equity market, behind banks and energy.Comprised mainly of transportation, engineering and construction stocks, industrials are generally seen as cyclical stocks and had blockbuster gains last year with a 24% rally. That was behind only tech and utilities.Last year Ballard Power Systems Inc.’s shares more than doubled after reporting a technology breakthrough that will reduce the amount of high-cost platinum used in its fuel-cell products. Air Canada came in second in the group after announcing a planned acquisition of tour operator Transat AT, accelerating its global presence in the leisure industry.Ballard’s surge has continued this year, climbing about 70% in January, as China signaled it wouldn’t further cut subsidies for electric vehicles, easing some fears for battery investors.One drag on the sector has been Bombardier Inc., which saw its stock slump and bonds tumble last week after the company said it was rethinking the A220 jet program with Airbus as it seeks ways to increase cash flow to help with paying down its $10 billion debt load. But, at a shadow of its former self, its contribution to the sectoral gauge is less than 1%.Markets -- Just The NumbersChart of The WeekEconomyCanadian businesses reported improved sentiment amid reduced concern about global trade conflicts, according to a Bank of Canada survey. Future sales like new orders have picked up, particularly outside of the energy sector, the Ottawa-based central bank’s fourth-quarter survey of executives found.Economists will see a big data dump on Jan. 22 with new housing price figures, inflation and the Bank of Canada’s rate decision.PoliticsPrime Minister Justin Trudeau’s bid to complete the Trans Mountain oil pipeline won a major victory Thursday as the nation’s top court rejected an appeal brought by British Columbia aimed at challenging the controversial project. The Supreme Court of Canada has dismissed the case, the court said in a statement.TrendingInCanada1\. St. John’s, Newfoundland, has declared a state of emergency as a blizzard ramps up with 75 centimeters of snow expected in the province.2\. And if you missed it, we taste-tested McDonald’s Corp. and Beyond Meat Inc.’s new PLT burger, which is getting a trial run in Ontario.\--With assistance from Steven Frank.To contact the reporter on this story: Divya Balji in Toronto at email@example.comTo contact the editors responsible for this story: Kyung Bok Cho at firstname.lastname@example.org, Jacqueline Thorpe, David ScanlanFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
LOS ANGELES, CA / ACCESSWIRE / January 20, 2020 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aurora Cannabis Inc. ("Aurora" ...
SAN FRANCISCO, CA / ACCESSWIRE / January 19, 2020 / Hagens Berman has filed a class action Complaint on behalf of investors in Aurora Cannabis Inc. (NYSE:ACB) . The firm urges ACB investors who have suffered ...
NEW YORK, NY / ACCESSWIRE / January 19, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
SAN FRANCISCO, CA / ACCESSWIRE / January 18, 2020 / Hagens Berman has filed a class action Complaint on behalf of investors in Aurora Cannabis Inc. (NYSE:ACB) . The firm urges ACB investors who have suffered ...
LOS ANGELES, CA / ACCESSWIRE / January 18, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aurora Cannabis Inc. ("Aurora" or "the Company") (NYSE:ACB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 11, 2019 and November 14, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 21, 2020.
SAN FRANCISCO, CA / ACCESSWIRE / January 17, 2020 / Hagens Berman has filed a class action Complaint on behalf of investors in Aurora Cannabis Inc. (NYSE: ACB) . The firm urges ACB investors who have suffered ...
Aurora Cannabis Inc. (ACB) closed the most recent trading day at $2.13, moving -0.93% from the previous trading session.